Epilepsy Leadership Empatica leads with FDA-cleared epilepsy monitoring solutions, including EpiMonitor, offering a proven platform for seizure detection, caregiver alerts, and remote patient monitoring which is ripe for expansion with newer regulatory milestones and international availability.

Global Expansion Recent launches and regulatory milestones have expanded EpiMonitor availability to Australia, New Zealand, and Canada, presenting cross-border selling opportunities to healthcare providers, trials, and patient populations seeking validated digital biomarkers and wearable-based monitoring.

Acquisition Momentum Strategic acquisitions in Parkinson’s and related neuroconditions (PKG Health, Global Kinetics) broaden Empatica’s addressable market in neurodegenerative and movement disorders, enabling cross-sell of wearables and digital health platform to a broader clinical audience.

Trial-Ready Platform Embrace family wearables and the EmbraceMini actigraphy device position Empatica as a turnkey solution for clinical trials, with validated digital measures, remote data collection, and partnerships like Mobilise-D enhancing outcomes research capabilities.

Diversified Health Measures The platform’s wide array of validated digital biomarkers enables trials across sleep, stress, epilepsy, movement, and more, offering upsell paths to institutions seeking comprehensive remote monitoring and data-driven insights for multiple indications.